Its proven for weight and blood sugar, though so far only approved for weight loss, with a diabetes filing expected later in 2026
Elecoglipron is an oral small molecule GLP-1 RA (receptor agonist), Vanita Aroda, MD, director of Diabetes Clinical Research at Brigham and Womens Hospital, associate professor of medicine at Harvard Medical School, and lead author of this study, told Medical News Today
One of the main benefits of GLP-1 is that it has been shown to be effective in helping people lose a significant amount of weight
Promoting Metabolic Health Recent research has also pointed to a link between glutathione and insulin sensitivity
Notably, the study found that orforglipron resulted in superior blood sugar reduction and weight loss for patients with type 2 diabetes
This correlates with visceral fat, which has stronger metabolic implications than subcutaneous fat